Pirfenidone gel in patients with localized scleroderma: a phase II study

Author: M. Rodríguez-Castellanos, A. Tlacuilo-Parra, S. Sánchez-Enríquez
Date Published: December-2014
Source: Arthritis Research & Therapy

Localized scleroderma is an inflammatory disease in its first stages and a fibrotic process in later stages, principally mediated by the transforming growth factor beta (TGF-?). To date there is no standard treatment. The objective of this study was to determine the effectiveness and safety of 8% pirfenidone gel in patients with localized scleroderma.MethodsThis was an open phase II clinical trial that included 12 patients.